Redsense is actively assessing potential impacts on its operations following the newly announced worldwide tariffs by President Donald Trump. While the tariffs introduce new uncertainties, the company remains in close dialogue with its customs brokers, U.S. distribution partners, and customers to monitor developments and coordinate responses. Although it is unclear if and how Medtech tariffs will affect medical devices, we are monitoring the situation carefully; including the focused efforts of numerous U.S. and EU-UK Medtech groups that are actively engaged in conversations with the White House.

"Our partners know we are all in this together, and all are committed to finding solutions that support everyone involved. With 3-6 months of product already in place at our US distribution partners, we don’t anticipate any disruption to customer demand or product availability in the short term" says Sebastien Bollue, CEO of Redsense Medical AB.

Separately, the anticipated launch of the Redsense Clamp—originally targeted for the end of Q1 2025—is currently still pending. The summative evaluation of the product’s usability study was submitted in February 2025, and the documentation remains under review. Feedback from the test house is still awaited.

The delay is primarily due to the high workload many test facilities and notified bodies have faced in the wake of MDR implementation, which has resulted in longer processing times across the industry. Redsense remains fully engaged with the test facility and their review process and is prepared to move forward promptly once approval is granted.

Contact information

For more information, please contact: 
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).